In a similar way, we also explored the potential combination of one immune checkpoint mAb with SHP2 inhibition (a targeted mechanism with increasing significance in cancer treatment), and the results also suggested better efficacy in the combination scenario at the preclinical level (Supplementary Figure S8). The gene discussed is PTPN11; the disease is cancer.